JP2020524151A - 睡眠障害組成物及びその治療 - Google Patents

睡眠障害組成物及びその治療 Download PDF

Info

Publication number
JP2020524151A
JP2020524151A JP2019569956A JP2019569956A JP2020524151A JP 2020524151 A JP2020524151 A JP 2020524151A JP 2019569956 A JP2019569956 A JP 2019569956A JP 2019569956 A JP2019569956 A JP 2019569956A JP 2020524151 A JP2020524151 A JP 2020524151A
Authority
JP
Japan
Prior art keywords
weight
pharmaceutical composition
extract
cannabis
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019569956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524151A5 (https=
Inventor
ゴードン、マラ
スミス、スチュワート
ウォッシャー、スチュワート
ウォッシャー、パトリツィア
カレリス、ハリー
Original Assignee
ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド
ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902338A external-priority patent/AU2017902338A0/en
Application filed by ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド, ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド filed Critical ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド
Publication of JP2020524151A publication Critical patent/JP2020524151A/ja
Publication of JP2020524151A5 publication Critical patent/JP2020524151A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2019569956A 2017-06-19 2018-06-19 睡眠障害組成物及びその治療 Ceased JP2020524151A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017902338A AU2017902338A0 (en) 2017-06-19 Sleep Disorder Composition and Treatment Thereof
AU2017902338 2017-06-19
AU2017904818A AU2017904818A0 (en) 2017-11-29 Sleep Disorder Compositions and Treatments Thereof
AU2017904818 2017-11-29
PCT/AU2018/050604 WO2018232448A1 (en) 2017-06-19 2018-06-19 COMPOSITION AGAINST SLEEP APNEA AND RELATED TREATMENTS

Publications (2)

Publication Number Publication Date
JP2020524151A true JP2020524151A (ja) 2020-08-13
JP2020524151A5 JP2020524151A5 (https=) 2021-07-26

Family

ID=62947713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569956A Ceased JP2020524151A (ja) 2017-06-19 2018-06-19 睡眠障害組成物及びその治療

Country Status (16)

Country Link
US (2) US20210145910A1 (https=)
EP (1) EP3641754A4 (https=)
JP (1) JP2020524151A (https=)
KR (1) KR20200104278A (https=)
CN (1) CN110944632A (https=)
AU (2) AU2018100837B4 (https=)
BR (1) BR112019026877A2 (https=)
CA (1) CA3065563C (https=)
CL (1) CL2019003635A1 (https=)
CO (1) CO2019013887A2 (https=)
IL (1) IL271503A (https=)
MX (1) MX387442B (https=)
NZ (1) NZ759963A (https=)
PE (1) PE20201163A1 (https=)
SG (1) SG11201912380XA (https=)
WO (1) WO2018232448A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505212A (ja) * 2021-01-28 2024-02-05 ジナーバ・ファーマシューティカルズ・インコーポレイテッド Ｃｂｄを用いた睡眠時無呼吸の処置
JP2024516682A (ja) * 2021-05-04 2024-04-16 ロンシー メディカ （ハイナン） カンパニー リミテッド 鼻腔用睡眠製剤

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900665VA (en) 2016-08-03 2019-02-27 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
CA3027876A1 (en) * 2018-12-18 2020-06-18 Tetra Bio-Pharma Cannabis compositions and methods
NL2022616B1 (en) * 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US10946054B1 (en) * 2019-10-08 2021-03-16 Jenny's Rose, LLC Therapeutic cannabis extracts
WO2021178579A1 (en) * 2020-03-03 2021-09-10 Alte Verde Llc Cannabis treatment of insomnia, pain, and skin conditions
US20220401378A1 (en) * 2020-03-09 2022-12-22 This Works Products Limited Compositions comprising functional fragrances and cannabis-derived compounds
CN112057894A (zh) * 2020-09-08 2020-12-11 云南工麻生物科技有限公司 一种提取大麻二酚的方法
CA3200651A1 (en) * 2020-12-04 2022-06-09 Joel Ernest George HARDY Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
CN112999218A (zh) * 2021-01-21 2021-06-22 龙麻(上海)医药研发有限责任公司 一种具有镇静助眠功效的组合物及用途
CN113143995A (zh) * 2021-01-21 2021-07-23 龙麻(上海)医药研发有限责任公司 一种大麻提取物舌下片及其制备工艺和应用
CN112791151B (zh) * 2021-02-20 2022-04-01 山东新稀宝股份有限公司 一种具有改善睡眠功能的组合物及应用
WO2022261662A1 (en) * 2021-06-09 2022-12-15 Demetrix, Inc. Regulation of the sleep/wake cycle using cannabinoid compounds
AU2023212130A1 (en) * 2022-01-27 2024-05-23 DEFINED RESEARCH, Inc. A cannabidiol (cbd) and terpene formulation that increases restorative sleep in humans

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511517A (ja) * 2000-10-17 2004-04-15 デルタ−９−ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング カンナビス植物材料からテトラヒドロカンナビノールとカンナビジオールとを含有する抽出物を製造する方法並びにカンナビス抽出物
WO2016064987A1 (en) * 2014-10-21 2016-04-28 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
WO2016191651A1 (en) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations
WO2018173049A1 (en) * 2017-03-20 2018-09-27 Kanabo Research Ltd. Vaporizable compositions comprising cannabinol
JP2019523283A (ja) * 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
KR101113162B1 (ko) 2002-08-14 2012-06-20 지더블유 파마 리미티드 식물물질로부터 약제학적 활성성분의 추출의 개량
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
WO2013165251A1 (en) 2012-05-03 2013-11-07 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising /\9-tetrahydrocannabinol and a method for preparing such an isolate
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US9763991B2 (en) * 2013-06-13 2017-09-19 Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
CN103355391A (zh) * 2013-08-13 2013-10-23 汕头大学医学院第一附属医院 一种五味健脑益智饼及其制备方法
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
HRP20221172T1 (hr) 2013-10-29 2023-02-03 Biotech Institute, Llc Uzgoj, proizvodnja, prerada i uporaba specijalnog sinsemilla kanabisa
WO2015068052A2 (en) 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
CN105010577A (zh) 2014-04-17 2015-11-04 天津市麦地那食品贸易有限公司 一种火麻、橄榄、葡萄籽、葵花籽调和油
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
AU2015308546A1 (en) 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
MX395015B (es) 2014-12-12 2025-03-24 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
CA2974292C (en) * 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
AU2016225026A1 (en) 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
WO2018023166A1 (en) 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US9649349B1 (en) * 2017-01-19 2017-05-16 Metamorphic Alchemy & Distillations, Inc. System and method for producing a terpene-enhanced cannibinoid concentrate
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
AU2018101357B4 (en) 2017-09-15 2022-03-17 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
CA3089994A1 (en) * 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
AU2018100924A4 (en) 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
MX2022015799A (es) 2020-06-12 2023-04-11 Zelira Therapeutics Operations Pty Ltd Composicion y metodo para el tratamiento del dolor cronico.
AU2021376539A1 (en) 2020-11-06 2023-06-15 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004511517A (ja) * 2000-10-17 2004-04-15 デルタ−９−ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング カンナビス植物材料からテトラヒドロカンナビノールとカンナビジオールとを含有する抽出物を製造する方法並びにカンナビス抽出物
WO2016064987A1 (en) * 2014-10-21 2016-04-28 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
WO2016191651A1 (en) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations
JP2019523283A (ja) * 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
WO2018173049A1 (en) * 2017-03-20 2018-09-27 Kanabo Research Ltd. Vaporizable compositions comprising cannabinol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMISTRY & BIODIVERSITY, vol. 4, JPN6022016432, 2007, pages 1729 - 1743, ISSN: 0005083978 *
浜島耕一 ほか, 薬学雑誌, vol. 103, no. 12, JPN6023024779, 1983, pages 1289 - 1297, ISSN: 0005083979 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505212A (ja) * 2021-01-28 2024-02-05 ジナーバ・ファーマシューティカルズ・インコーポレイテッド Ｃｂｄを用いた睡眠時無呼吸の処置
JP2024516682A (ja) * 2021-05-04 2024-04-16 ロンシー メディカ （ハイナン） カンパニー リミテッド 鼻腔用睡眠製剤

Also Published As

Publication number Publication date
AU2018100837A4 (en) 2018-07-26
CO2019013887A2 (es) 2020-04-01
US20230270808A1 (en) 2023-08-31
PE20201163A1 (es) 2020-10-28
MX2019015315A (es) 2020-02-17
US12239680B2 (en) 2025-03-04
AU2018286647B2 (en) 2024-03-28
EP3641754A4 (en) 2021-03-10
IL271503A (en) 2020-02-27
CA3065563A1 (en) 2018-12-27
SG11201912380XA (en) 2020-01-30
KR20200104278A (ko) 2020-09-03
CN110944632A (zh) 2020-03-31
AU2018286647A1 (en) 2020-01-16
EP3641754A1 (en) 2020-04-29
NZ759963A (en) 2022-07-01
WO2018232448A1 (en) 2018-12-27
US20210145910A1 (en) 2021-05-20
BR112019026877A2 (pt) 2020-06-30
CA3065563C (en) 2023-06-13
CL2019003635A1 (es) 2020-06-19
MX387442B (es) 2025-03-18
AU2018100837B4 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
US12239680B2 (en) Sleep disorder compositions and treatments thereof
US12239628B2 (en) Cannabis composition
US20230364052A1 (en) Composition and method for treating autism
NZ789786A (en) Sleep Disorder Compositions and Treatments Thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210609

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230320

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230428

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230616

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250724

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20251028